tiprankstipranks
Trending News
More News >
Narayana Hrudayalaya Ltd. (IN:NH)
:NH
India Market

Narayana Hrudayalaya Ltd. (NH) AI Stock Analysis

Compare
8 Followers

Top Page

IN:NH

Narayana Hrudayalaya Ltd.

(NH)

Select Model
Select Model
Select Model
Outperform 71 (OpenAI - 5.2)
Rating:71Outperform
Price Target:
₹1,923.00
▲(9.48% Upside)
Action:ReiteratedDate:11/18/25
Narayana Hrudayalaya Ltd. has a strong financial performance with robust revenue growth and profitability, which is the most significant factor in its overall score. The technical analysis indicates bullish momentum, although the stock appears overvalued based on its P/E ratio. The absence of earnings call data and corporate events limits further insights.
Positive Factors
Robust revenue growth
Sustained high revenue growth and a near doubling of reported top-line over four years signal durable demand and improving market penetration. This scale supports margin improvements, fixed-cost absorption, and funds reinvestment into facilities and specialty services, enhancing long-term competitiveness.
Tertiary-care multi-specialty network
A portfolio centered on high-complexity tertiary specialties (notably cardiac sciences) creates sustainable competitive advantages: referral pipelines, higher-value procedures, and brand recognition. Diversified specialties reduce reliance on any single service line and support durable volume and pricing power.
Strong operating cash conversion & improving gross margins
Consistent positive operating cash flow and improving gross margins indicate efficient service delivery and cost control. Reliable cash generation enables capital investment and network scale without immediate dilution, underpinning long-term financial flexibility despite episodic capex spikes.
Negative Factors
Rising total debt
An upward trend in total debt increases leverage risk and interest obligations. If revenue or margins soften, higher debt reduces financial flexibility for capex or hiring, elevates refinancing risk, and could force cost cutting or slower expansion over the next several quarters.
EBITDA margin decline
A falling EBITDA margin points to margin compression from higher operating costs or aggressive growth investment. Sustained declines would weaken cash flow generation and return on capital, making it harder to fund expansion internally and potentially pressuring profitability over the medium term.
Negative free cash flow in 2025
Negative free cash flow driven by elevated capex reduces liquidity and raises dependence on external financing. Combined with rising debt, this can constrain strategic optionality, slow future investment if funding tightens, and increase sensitivity to operating performance in upcoming quarters.

Narayana Hrudayalaya Ltd. (NH) vs. iShares MSCI India ETF (INDA)

Narayana Hrudayalaya Ltd. Business Overview & Revenue Model

Company DescriptionNarayana Hrudayalaya Limited provides medical and healthcare services. The company operates and maintains hospitals, clinics, health centers, nursing homes, and other related activities. It offers services in various specialties, including cardiology, cardiac surgery, nephrology, urology, neurology, neuro-surgery, endocrinology, orthopedics, internal medicines, obstetrics, gynecology, pediatrics, neonatology, gastroenterology, and oncology. As of June 30, 2022, the company operated through a network of 19 owned/operated hospitals, 2 managed hospitals, 4 heart centers, and 18 clinics and information centers in India, as well as a hospital in the Cayman Islands. It also provides healthcare consultancy services, including licensing of ERP solutions. The company was incorporated in 2000 and is headquartered in Bengaluru, India.
How the Company Makes MoneyNarayana Hrudayalaya Ltd. generates revenue primarily through patient services, which include inpatient and outpatient treatments, surgical procedures, and diagnostic services. The company operates on a fee-for-service model, where patients are charged for the services they receive. In addition to direct patient care, NH also earns revenue through partnerships with insurance companies, where they provide medical services to insured patients. Furthermore, NH has expanded its revenue streams by offering telemedicine services and health check-up packages. The company's focus on affordability and quality has attracted a significant patient base, contributing to its overall earnings.

Narayana Hrudayalaya Ltd. Financial Statement Overview

Summary
Narayana Hrudayalaya Ltd. demonstrates strong financial health with robust revenue growth and profitability. The balance sheet reflects prudent financial management, although increasing debt levels need monitoring. Cash flow management is generally effective, despite the recent dip in free cash flow.
Income Statement
85
Very Positive
Narayana Hrudayalaya Ltd. has shown a strong financial performance with consistent revenue growth, increasing from 25.8 billion in 2021 to 54.8 billion in 2025. The gross profit margin has improved, indicating better cost management. The net profit margin has remained stable, demonstrating profitability. However, the decline in EBITDA margin from 2024 to 2025 suggests potential cost pressures or investment in growth.
Balance Sheet
78
Positive
The company maintains a healthy balance sheet with a solid equity position. The debt-to-equity ratio is manageable, indicating prudent financial leverage. An increasing equity ratio suggests effective asset management. However, the rising total debt from 2022 to 2025 could pose future financial risks if not managed carefully.
Cash Flow
70
Positive
The cash flow position is relatively stable, with positive operating cash flow consistently over the years. Despite a dip in free cash flow in 2025 due to higher capital expenditure, the overall cash flow management remains robust. The operating cash flow to net income ratio indicates efficient conversion of income into cash, although the negative free cash flow in 2025 warrants attention.
BreakdownTTMMar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Income Statement
Total Revenue57.49B54.83B48.90B45.30B37.01B25.84B
Gross Profit24.69B21.12B18.41B16.76B12.13B6.42B
EBITDA12.59B12.28B11.02B9.31B6.19B1.43B
Net Income7.85B7.90B7.89B6.06B3.42B-143.04M
Balance Sheet
Total Assets0.0072.65B56.25B41.62B31.30B27.70B
Cash, Cash Equivalents and Short-Term Investments16.27B16.27B11.04B6.51B3.01B2.39B
Total Debt0.0024.28B16.27B8.84B7.23B8.26B
Total Liabilities-36.28B36.37B27.39B20.30B16.40B16.49B
Stockholders Equity36.28B36.26B28.84B21.31B14.89B11.20B
Cash Flow
Free Cash Flow0.00-961.81M959.93M5.63B2.34B2.39B
Operating Cash Flow0.009.86B10.67B10.85B4.85B3.09B
Investing Cash Flow0.00-13.25B-14.58B-11.74B-2.67B-1.13B
Financing Cash Flow0.005.44B4.88B877.41M-1.59B-1.98B

Narayana Hrudayalaya Ltd. Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1756.45
Price Trends
50DMA
1833.48
Negative
100DMA
1842.99
Negative
200DMA
1845.63
Negative
Market Momentum
MACD
-8.03
Positive
RSI
43.57
Neutral
STOCH
21.26
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NH, the sentiment is Negative. The current price of 1756.45 is below the 20-day moving average (MA) of 1812.02, below the 50-day MA of 1833.48, and below the 200-day MA of 1845.63, indicating a bearish trend. The MACD of -8.03 indicates Positive momentum. The RSI at 43.57 is Neutral, neither overbought nor oversold. The STOCH value of 21.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:NH.

Narayana Hrudayalaya Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
74
Outperform
₹711.95B18.870.33%7.33%-3.79%
71
Outperform
₹361.40B75.820.24%14.72%8.37%
67
Neutral
₹81.00B-247.4717.58%-38.20%
65
Neutral
₹281.58B114.0125.74%1.41%
65
Neutral
₹298.69B83.790.04%15.78%15.01%
61
Neutral
₹695.24B86.120.11%15.33%54.62%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:NH
Narayana Hrudayalaya Ltd.
1,768.45
195.01
12.39%
IN:AUROPHARMA
Aurobindo Pharma Ltd
1,225.80
116.17
10.47%
IN:FORTIS
Fortis Healthcare Ltd.
920.90
274.71
42.51%
IN:HCG
HealthCare Global Enterprises Ltd.
542.50
35.44
6.99%
IN:KIMS
Krishna Institute of Medical Sciences Limited
703.70
177.30
33.68%
IN:MEDANTA
Global Health Limited
1,111.25
-140.60
-11.23%

Narayana Hrudayalaya Ltd. Corporate Events

Narayana Hrudayalaya Sets April 2026 Creditor and Shareholder Meetings for Restructuring Scheme
Feb 26, 2026

Narayana Hrudayalaya has scheduled meetings of its shareholders and secured and unsecured creditors, alongside those of NH Integrated Care Private Limited, on 2 April 2026 via video conferencing, as directed by the National Company Law Tribunal in Bengaluru. The meetings will vote on a Scheme of Arrangement under the Companies Act that will govern the proposed restructuring between the demerged NH Integrated Care and Narayana Hrudayalaya as the resulting company.

The company has set a remote e-voting window from 30 March to 1 April 2026 to enable stakeholders to cast votes on the scheme ahead of the meetings, and has circulated the notices electronically and by post where needed. The process marks a key step in formalising the corporate reorganisation, with outcomes likely to influence Narayana Hrudayalaya’s capital structure and its future integration with NH Integrated Care, with implications for both creditors and equity holders.

Narayana Hrudayalaya Sets April Meetings on NH Integrated Care Demerger Scheme
Feb 26, 2026

Narayana Hrudayalaya Ltd. has scheduled meetings of its shareholders and secured and unsecured creditors, along with those of NH Integrated Care Private Limited, on April 2, 2026, following directions from the National Company Law Tribunal’s Bengaluru Bench. These meetings, to be held via video conferencing or other audio-visual means, will vote on a Scheme of Arrangement under the Companies Act that contemplates NH Integrated Care as the demerged entity and Narayana Hrudayalaya as the resulting company.

The company has outlined a detailed timetable, with separate sessions for equity shareholders, secured creditors, and unsecured creditors of both Narayana Hrudayalaya and NH Integrated Care, and has enabled remote e-voting from March 30 to April 1, 2026. By moving the process forward under the oversight of the NCLT and providing multiple participation channels and advance dispatch of notices, the company is progressing toward a corporate restructuring that could realign its integrated care business within the broader Narayana Health group structure, potentially affecting capital structure and stakeholder claims once approved.

Narayana Hrudayalaya Publishes NCLT Notice on Merger of Meridian Medical Research & Hospital
Feb 7, 2026

Narayana Hrudayalaya Limited, a leading hospital and healthcare services provider, operates through a network of medical institutions and subsidiaries across India, offering a range of clinical and research-focused healthcare services.

The company has announced that, pursuant to an order of the National Company Law Tribunal (NCLT) Bengaluru Bench dated 30 January 2026, it has published a statutory NCLT-3A advertisement detailing a petition for the proposed amalgamation of its subsidiary Meridian Medical Research & Hospital Ltd. with Narayana Hrudayalaya Limited. The notice, carried in Business Standard (all-India, English) and Kannada Prabha (Karnataka, Kannada) on 7 February 2026, provides information on the merger petition and the scheduled NCLT hearing on 27 February 2026, marking a key procedural step in consolidating the subsidiary into the parent company and potentially streamlining the group’s hospital and research operations.

Narayana Hrudayalaya Shareholders and Creditors Clear Scheme of Arrangement with Meridian Medical Research & Hospital
Jan 21, 2026

Narayana Hrudayalaya Limited has reported the voting results and Scrutinizer’s Report for National Company Law Tribunal-convened meetings of its equity shareholders, secured creditors, unsecured loan creditors and unsecured trade creditors held on 19 January 2026 via video conferencing, in line with SEBI disclosure requirements. The stakeholders overwhelmingly approved a special resolution for a Scheme of Arrangement between Meridian Medical Research & Hospital Ltd as transferor company and Narayana Hrudayalaya Limited as transferee company under Sections 230–232 of the Companies Act, 2013, with near-unanimous e-voting support across promoter, institutional and non-institutional categories; the outcome, now disclosed to stock exchanges and on the company and NSDL websites, clears a key procedural hurdle for the proposed restructuring, potentially strengthening Narayana Hrudayalaya’s hospital portfolio and consolidating its presence in the healthcare services market, subject to remaining regulatory and tribunal approvals.

Narayana Hrudayalaya Forms Wholly Owned Subsidiary to Drive Northern India Expansion
Jan 16, 2026

Narayana Hrudayalaya Ltd. has incorporated a new wholly owned subsidiary, Narayana Healthcare North Private Limited, with an authorised capital of Rs 10 lakh and paid-up capital of Rs 5 lakh, to operate in the hospital and healthcare sector. The subsidiary has been set up to carry on healthcare services, including hospital operations and health and wellness management, and is intended to serve as a focused vehicle to deepen and optimize the company’s growing presence in northern India, potentially strengthening its regional positioning and operational focus in that market.

Narayana Hrudayalaya Announces Demerger to Enhance Healthcare Focus
Dec 12, 2025

Narayana Hrudayalaya Ltd. has approved a Scheme of Arrangement for the demerger of its Clinical Services undertaking from NH Integrated Care Private Limited to Narayana Hrudayalaya Limited. This strategic move is aimed at enhancing shareholder value by allowing NHIC to focus on its preventive healthcare business while optimizing patient care and resource efficiency through integrated operations within NHL. The demerger is subject to necessary statutory and regulatory approvals, including those from the National Company Law Tribunal and other relevant authorities.

Narayana Hrudayalaya Announces Strategic Demerger to Enhance Healthcare Services
Dec 12, 2025

Narayana Hrudayalaya Ltd. has approved a Scheme of Arrangement involving the demerger of its Clinical Services from NH Integrated Care Private Limited into Narayana Hrudayalaya Limited. This strategic move aims to enhance operational efficiency by unifying patient care pathways and optimizing resource deployment. The demerger is expected to allow NH Integrated Care to focus on its preventive healthcare business, potentially increasing shareholder value by concentrating on this niche market.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Nov 18, 2025